rts logo

CRISPR Therapeutics AG (CRSP) Is Up 8.88% in 2024 With Lots of Room to Run

CRISPR Therapeutics AG (NASDAQ: CRSP) is 8.88% higher on its value in year-to-date trading and has touched a low of $37.55 and a high of $91.10 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CRSP stock was last observed hovering at around $70.16 in the last trading session, with the day’s loss setting it -2.0%.

Currently trading at $68.16, the stock is -10.10% and -7.04% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.6 million and changing -2.85% at the moment leaves the stock 15.07% off its SMA200. CRSP registered 53.69% gain for a year compared to 6-month gain of 47.82%. The firm has a 50-day simple moving average (SMA 50) of $10.86 and a 200-day simple moving average (SMA200) of -$19.82.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The stock witnessed a -22.26% loss in the last 1 month and extending the period to 3 months gives it a 4.93%, and is -8.51% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.39% over the week and 4.19% over the month.

CRISPR Therapeutics AG (CRSP) has around 407 employees, a market worth around $5.74B and $371.21M in sales. Profit margin for the company is -41.38%. Distance from 52-week low is 81.52% and -25.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-7.29%).

CRISPR Therapeutics AG quarterly earnings per share for the current quarter are estimated at -$1.41 with sales reaching $17.91M over the same period.The EPS is expected to shrink by -199.14% this year, but quarterly earnings will post -71.00% year-over-year. Quarterly sales are estimated to shrink -82.10% in year-over-year returns.

CRISPR Therapeutics AG (CRSP) Top Institutional Holders

623 institutions hold shares in CRISPR Therapeutics AG (CRSP), with institutional investors hold 67.78% of the company’s shares. The shares outstanding are 80.04M, and float is at 79.80M with Short Float at 18.45%. Institutions hold 66.81% of the Float.

The top institutional shareholder in the company is ARK Investment Management, LLC with over 7.16 million shares valued at $325.13 million. The investor’s holdings represent 9.02% of the CRSP Shares outstanding. As of Jun 29, 2023, the second largest holder is Capital International Investors with 6.07 million shares valued at $340.75 million to account for 7.64% of the shares outstanding. The other top investors are T. Rowe Price Investment Management, Inc. which holds 3.65 million shares representing 4.59% and valued at over $204.72 million, while Nikko Asset Management Americas, Inc. holds 4.45% of the shares totaling 3.53 million with a market value of $198.36 million.

CRISPR Therapeutics AG (CRSP) Insider Activity

The most recent transaction is an insider sale by Kulkarni Samarth,the company’sChief Executive Officer. SEC filings show that Kulkarni Samarth sold 20,000 shares of the company’s common stock on Mar 15 ’24 at a price of $72.48 per share for a total of $1.45 million. Following the sale, the insider now owns 0.21 million shares.

CRISPR Therapeutics AG disclosed in a document filed with the SEC on Mar 15 ’24 that Prasad Raju (Chief Financial Officer) sold a total of 3,524 shares of the company’s common stock. The trade occurred on Mar 15 ’24 and was made at $72.69 per share for $0.26 million. Following the transaction, the insider now directly holds 6476.0 shares of the CRSP stock.

Still, SEC filings show that on Mar 12 ’24, Kulkarni Samarth (Chief Executive Officer) disposed off 4,583 shares at an average price of $74.44 for $0.34 million. The insider now directly holds 208,122 shares of CRISPR Therapeutics AG (CRSP).

Related Posts